Patents by Inventor Robert E. Davis

Robert E. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220280517
    Abstract: The disclosure relates to methods of administering comprising administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and/or prophylaxis of renal disorders, such as chronic kidney disease. Related compounds and methods of making are further defined.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 8, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert E. DAVIS, Peng LI
  • Publication number: 20220241265
    Abstract: Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that SHT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: September 14, 2021
    Publication date: August 4, 2022
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Publication number: 20210379072
    Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.
    Type: Application
    Filed: October 21, 2019
    Publication date: December 9, 2021
    Inventors: Robert E. DAVIS, Kimberly E. VANOVER
  • Publication number: 20210369715
    Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.
    Type: Application
    Filed: June 2, 2021
    Publication date: December 2, 2021
    Inventors: Peng Li, Robert E. Davis
  • Publication number: 20210340847
    Abstract: An interchangeable module configured to be used in an integrated perforating gun and setting tool system, the interchangeable module having a body having a chamber, a first electrical connection located at a first end of the chamber, and a second electrical connection located at a second end of the chamber. The first end is opposite to the second end. An addressable switch located inside the chamber, the addressable switch has a digital address. A connection unit located inside the chamber and configured to electrically connect the addressable switch to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool, and the first and second electrical connections are electrically connected to the addressable switch.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Inventors: Robert E. DAVIS, Terrell SALTARELLI, Jason ANSLEY
  • Patent number: 11078765
    Abstract: An interchangeable module is configured to be used in an integrated perforating gun and setting tool system. The interchangeable module includes a body having first external threads; an addressable switch located inside the body; and a connection unit located inside the body and configured to electrically connect to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: August 3, 2021
    Assignee: GEODYNAMICS, INC.
    Inventors: Robert E. Davis, Terrell Saltarelli, Jason Ansley
  • Publication number: 20210186962
    Abstract: The present disclosure relates to the treatment of schizophrenia in adults, comprising the administration of pharmaceutical capsules comprising 42 mg of lumateperone (60 mg of lumateperone tosylate).
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Robert E. DAVIS, Kimberly VANOVER
  • Patent number: 10920544
    Abstract: A downhole system includes a switch sub holding a gun switch and an adapter attached to the switch sub and holding an igniter switch. The gun switch is configured to detonate a detonator, and the igniter switch is configured to ignite an igniter system.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: February 16, 2021
    Assignee: GEODYNAMICS, INC.
    Inventors: Shelby L. Sullivan, Johnny Joslin, Robert E. Davis, John T. Hardesty, Aaron Douglas Holmberg
  • Patent number: 10914147
    Abstract: There is an igniter system for igniting an energetic material. The igniter system includes a housing having a bore; an igniter located inside the bore; a ground wire directly connected to the igniter; and a signal wire directly connected to the igniter. The ground wire and the signal wire form an electrical circuit with the igniter for igniting the energetic material.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: February 9, 2021
    Assignee: GEODYNAMICS, INC.
    Inventors: Shelby L. Sullivan, Johnny Joslin, Robert E. Davis, John T. Hardesty
  • Publication number: 20200332630
    Abstract: An interchangeable module is configured to be used in an integrated perforating gun and setting tool system. The interchangeable module includes a body having first external threads; an addressable switch located inside the body; and a connection unit located inside the body and configured to electrically connect to an initiating device. The interchangeable module is configured to be used (1) between a first gun cluster and a second gun cluster and (2) between a distal gun cluster and a setting tool.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 22, 2020
    Applicant: GEODYNAMICS, INC.
    Inventors: Robert E. DAVIS, Terrell SALTARELLI, Jason ANSLEY
  • Publication number: 20200323836
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonist may confer antipsychotic and ant dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: November 18, 2019
    Publication date: October 15, 2020
    Applicant: ACADIA Pharmaceuticals Inc.
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Patent number: 10525046
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: January 7, 2020
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Patent number: 10472939
    Abstract: There is a downhole tool that includes a switch sub having a bore and a bulkhead extending along a longitudinal axis, wherein the bulkhead has a bulkhead bore that fluidly communicates with (i) the bore and (ii) an outside of the switch sub; and an igniter system located inside the bulkhead. The igniter system is configured to ignite an energetic material.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: November 12, 2019
    Assignee: GEODYNAMICS, INC.
    Inventors: Shelby L. Sullivan, Johnny Joslin, Robert E. Davis, John T. Hardesty
  • Publication number: 20190136673
    Abstract: A downhole system includes a switch sub holding a gun switch and an adapter attached to the switch sub and holding an igniter switch. The gun switch is configured to detonate a detonator, and the igniter switch is configured to ignite an igniter system.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Applicants: GEODYNAMICS, INC., GEODYNAMICS, INC.
    Inventors: Shelby L. SULLIVAN, Johnny JOSLIN, Robert E. DAVIS, John T. HARDESTY, Aaron Douglas HOLMBERG
  • Publication number: 20190106969
    Abstract: There is an igniter system for igniting an energetic material. The igniter system includes a housing having a bore; an igniter located inside the bore; a ground wire directly connected to the igniter; and a signal wire directly connected to the igniter. The ground wire and the signal wire form an electrical circuit with the igniter for igniting the energetic material.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 11, 2019
    Inventors: Shelby L. SULLIVAN, Johnny JOSLIN, Robert E. DAVIS, John T. HARDESTY
  • Publication number: 20190048694
    Abstract: There is a downhole tool that includes a switch sub having a bore and a bulkhead extending along a longitudinal axis, wherein the bulkhead has a bulkhead bore that fluidly communicates with (i) the bore and (ii) an outside of the switch sub; and an igniter system located inside the bulkhead. The igniter system is configured to ignite an energetic material.
    Type: Application
    Filed: June 27, 2018
    Publication date: February 14, 2019
    Inventors: Shelby L. SULLIVAN, Johnny JOSLIN, Robert E. DAVIS, John T. HARDESTY
  • Publication number: 20190030015
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 31, 2019
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Patent number: 10036236
    Abstract: There is a downhole tool that includes a switch sub having a bore and a bulkhead extending along a longitudinal axis, wherein the bulkhead has a bulkhead bore that fluidly communicates with (i) the bore and (ii) an outside of the switch sub; and an igniter system located inside the bulkhead. The igniter system is configured to ignite an energetic material.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 31, 2018
    Assignee: GEODYNAMICS, INC.
    Inventors: Shelby L. Sullivan, Johnny Joslin, Robert E. Davis, John T. Hardesty
  • Patent number: 10028944
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 24, 2018
    Assignee: ACADIA PHARMACEUTICALS INC.
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
  • Publication number: 20170209424
    Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Type: Application
    Filed: January 3, 2017
    Publication date: July 27, 2017
    Inventors: David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam